Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | AGTR1 | P30556 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 3/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | IDO1 | P14902 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | CASR | P41180 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Guaifenesin SCHEMBL31161209 | 1.00 | CYP1A2 (1.00) | CYP1A2LMNAAGTR1KDM4ESMN1; SMN2 | |
| Guaifenesin SCHEMBL160234 | 1.00 | CYP1A2 (1.00) | CYP1A2LMNAAGTR1KDM4ESMN1; SMN2 | |
| Guaifenesin SCHEMBL4322 | 1.00 | CYP1A2 (1.00) | CYP1A2LMNAAGTR1KDM4ESMN1; SMN2 | |
| Guaifenesin SCHEMBL4321 | 1.00 | CYP1A2 (1.00) | CYP1A2LMNAAGTR1KDM4ESMN1; SMN2 | |
| Guaifenesin SCHEMBL4894727 | 0.98 | CYP1A2 (0.96) | CYP1A2LMNAAGTR1KDM4ESMN1; SMN2 | |
| Guaifenesin SCHEMBL2459821 | 0.98 | CYP1A2 (0.96) | CYP1A2LMNAAGTR1KDM4ESMN1; SMN2 | |
| Guaifenesin SCHEMBL28898302 | 0.92 | CYP1A2 (0.84) | CYP1A2LMNAAGTR1KDM4ESMN1; SMN2 | |
| Guaifenesin SCHEMBL28062894 | 0.92 | CYP1A2 (0.84) | CYP1A2LMNAAGTR1KDM4ESMN1; SMN2 | |
| SCHEMBL29941729 | 0.90 | LMNA (0.82) | CYP1A2LMNAAGTR1KDM4ESMN1; SMN2 | |
| SCHEMBL2328960 | 0.90 | LMNA (0.82) | CYP1A2LMNAAGTR1KDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119998352-A | Epoxy resin curing agent, epoxy resin composition, sealing material, electrically conductive material, thermally conductive material, adhesive for camera module, adhesive for structure, matrix resin for fiber-reinforced plastic, impregnating and fixing material, interlayer insulating film, film-type solder resist, sealing sheet, electrically conductive film, anisotropic electrically conductive film, thermally conductive film, and method for producing dyed cured product | 旭化成株式会社 | 2025-05-13 | — | — | CN | claimed |
| WO-2025084921-A1 | DEVELOPMENT OF FORMULATIONS FOR THE MANAGEMENT AND ANTIVIRAL, IMMUNOMODULATORY AND ANTI-INFLAMMATORY TREATMENT OF THE NEW SARS-COV-2 INFECTION AND THE ASSOCIATED DISEASE, COVID-19, AND ITS VARIANTS, FORMULATED FROM GLYCYRRHIZIC ACID SALT AND THE DERIVATIVES THEREOF | DRAGUSTINOVIS MARIA ESTHER (MX) | 2025-04-24 | — | — | WO | claimed |
| CN-112029717-B | Serum-free in vitro domestication culture of human mesenchymal stem cells | 深圳博雅感知药业有限公司 | 2023-11-03 | — | — | CN | claimed |
| CN-119998352-A | Epoxy resin curing agent, epoxy resin composition, sealing material, electrically conductive material, thermally conductive material, adhesive for camera module, adhesive for structure, matrix resin for fiber-reinforced plastic, impregnating and fixing material, interlayer insulating film, film-type solder resist, sealing sheet, electrically conductive film, anisotropic electrically conductive film, thermally conductive film, and method for producing dyed cured product | 旭化成株式会社 | 2025-05-13 | — | — | CN | disclosed |
| EP-4547220-A1 | A STABLE ORAL LIQUID COMPOSITION COMPRISING TERBUTALINE & GUAIFENESIN | Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi (TR) | 2025-05-07 | — | — | EP | disclosed |
| WO-2025084921-A1 | DEVELOPMENT OF FORMULATIONS FOR THE MANAGEMENT AND ANTIVIRAL, IMMUNOMODULATORY AND ANTI-INFLAMMATORY TREATMENT OF THE NEW SARS-COV-2 INFECTION AND THE ASSOCIATED DISEASE, COVID-19, AND ITS VARIANTS, FORMULATED FROM GLYCYRRHIZIC ACID SALT AND THE DERIVATIVES THEREOF | DRAGUSTINOVIS MARIA ESTHER (MX) | 2025-04-24 | — | — | WO | disclosed |
| US-20240382417-A1 | Compositions Comprising Guaifenesin and Eriodictyol | SYMRISE AG (DE) | 2024-11-21 | — | — | US | disclosed |
| CN-118084633-A | Purification method of guaifenesin | 开封明仁药业有限公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-117580888-A | Epoxy resin composition, film, method for producing film, and cured product | 旭化成株式会社 | 2024-02-20 | — | — | CN | disclosed |
| WO-2024005758-A1 | A STABLE ORAL LIQUID COMPOSITION COMPRISING TERBUTALINE & GUAIFENESIN | ABDI IBRAHIM ILAC SANAYI VE TICARET ANONIM SIRKETI (TR) | 2024-01-04 | — | — | WO | disclosed |
| CN-112029717-B | Serum-free in vitro domestication culture of human mesenchymal stem cells | 深圳博雅感知药业有限公司 | 2023-11-03 | — | — | CN | disclosed |
| CN-116615509-A | Epoxy resin composition, adhesive film, printed circuit board, semiconductor chip package, semiconductor device, and method for using adhesive film | 旭化成株式会社 | 2023-08-18 | — | — | CN | disclosed |
| CN-115725055-A | Epoxy resin composition | 旭化成株式会社 | 2023-03-03 | — | — | CN | disclosed |
| CN-115043811-A | Preparation method of 4- [ (2-methoxyphenoxy) methyl ] -1, 3-dioxolane-2-one | 苏州敬业医药化工有限公司 | 2022-09-13 | — | — | CN | disclosed |
| WO-2022138343-A1 | EPOXY RESIN COMPOSITION, ADHESIVE FILM, PRINTED WIRING BOARD, SEMICONDUCTOR CHIP PACKAGE, SEMICONDUCTOR DEVICE, AND METHOD FOR USING ADHESIVE FILM | 旭化成株式会社 | 2022-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240382417-A1 | Compositions Comprising Guaifenesin and Eriodictyol | ERLIN1, TAS2R38, TAS2R39 | CYP1A2 570/4885LMNA 2050/4885AGTR1 2130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.